Index S&P 500
P/E 21.54
EPS (ttm) 2.64
Insider Own 1.19%
Shs Outstand 224.29M
Perf Week -1.30%
Market Cap 12.79B
Forward P/E 10.64
EPS next Y 5.35
Insider Trans -0.35%
Shs Float 221.85M
Perf Month -5.02%
Income 597.60M
PEG 0.96
EPS next Q 0.86
Inst Own 99.05%
Short Float 3.56%
Perf Quarter -9.11%
Sales 3.70B
P/S 3.46
EPS this Y 25.25%
Inst Trans 0.60%
Short Ratio 4.62
Perf Half Y -3.62%
Book/sh 23.14
P/B 2.46
EPS next Y 21.20%
ROA 9.41%
Short Interest 7.91M
Perf Year -18.97%
Cash/sh 16.28
P/C 3.50
EPS next 5Y 22.50%
ROE 12.50%
52W Range 50.27 - 76.04
Perf YTD -9.27%
Dividend Est. -
P/FCF 27.57
EPS past 5Y 38.99%
ROI 11.42%
52W High -25.08%
Beta 0.65
Dividend TTM -
Quick Ratio 3.69
Sales past 5Y 14.55%
Gross Margin 91.47%
52W Low 13.33%
ATR (14) 1.31
Dividend Ex-Date -
Current Ratio 3.75
EPS Y/Y TTM 73.98%
Oper. Margin 17.64%
RSI (14) 41.41
Volatility 1.67% 2.30%
Employees 2524
Debt/Eq 0.01
Sales Y/Y TTM 8.87%
Profit Margin 16.17%
Recom 1.96
Target Price 74.59
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q 602.37%
Payout 0.00%
Rel Volume 1.10
Prev Close 57.12
Sales Surprise 1.06%
EPS Surprise -7.85%
Sales Q/Q 9.35%
Earnings Feb 13 BMO
Avg Volume 1.71M
Price 56.97
SMA20 -2.62%
SMA50 -3.77%
SMA200 -5.11%
Trades
Volume 1,883,103
Change -0.26%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Initiated
Jefferies
Buy
$81
Feb-14-24 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Dec-13-23 Upgrade
Leerink Partners
Market Perform → Outperform
$78
Dec-04-23 Upgrade
Guggenheim
Neutral → Buy
$86
Nov-21-23 Downgrade
Goldman
Buy → Neutral
$98 → $65
Jul-25-23 Initiated
Citigroup
Buy
$82
May-04-23 Downgrade
BofA Securities
Buy → Neutral
$84
Apr-10-23 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$81 → $79
Mar-24-23 Upgrade
SVB Securities
Underperform → Market Perform
$61
Jan-31-23 Initiated
Piper Sandler
Overweight
$100
Aug-03-22 Downgrade
Guggenheim
Buy → Neutral
Aug-03-22 Downgrade
Evercore ISI
Outperform → In-line
$90 → $78
Jul-28-22 Initiated
Wells Fargo
Equal Weight
$76
Feb-09-22 Downgrade
SVB Leerink
Mkt Perform → Underperform
$60 → $56
Jan-18-22 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$78 → $90
Nov-19-21 Initiated
BMO Capital Markets
Market Perform
$75
Jul-20-21 Upgrade
The Benchmark Company
Hold → Buy
$89
Feb-10-21 Downgrade
SVB Leerink
Mkt Perform → Underperform
$70
Jan-07-21 Initiated
Truist
Buy
$120
Jan-04-21 Upgrade
Guggenheim
Neutral → Buy
Show Previous Ratings
Mar-26-24 02:47PM
Mar-17-24 08:50AM
Mar-15-24 10:37AM
Mar-14-24 11:30AM
08:18AM
01:52PM
Loading…
Mar-12-24 01:52PM
Mar-11-24 01:02PM
07:18AM
Mar-10-24 04:05PM
04:05PM
Mar-07-24 03:00PM
Mar-04-24 08:00AM
Mar-03-24 08:29AM
Feb-29-24 10:19AM
07:30AM
01:10PM
Loading…
Feb-28-24 01:10PM
(Thomson Reuters StreetEvents)
Feb-27-24 04:08PM
Feb-26-24 03:20PM
Feb-21-24 04:50PM
Feb-15-24 08:00AM
Feb-14-24 09:32AM
01:15AM
(Thomson Reuters StreetEvents)
12:12AM
Feb-13-24 05:43PM
11:37AM
09:30AM
08:26AM
08:25AM
07:38AM
07:35AM
07:34AM
Loading…
07:34AM
(Associated Press Finance)
07:00AM
Feb-09-24 11:03AM
09:15AM
Feb-07-24 08:55AM
Feb-06-24 04:30AM
Feb-05-24 06:54PM
(Investor's Business Daily)
04:46PM
Jan-31-24 07:33PM
Jan-30-24 11:07AM
Jan-26-24 09:12AM
Jan-24-24 08:39AM
Jan-23-24 08:00AM
Jan-18-24 04:00PM
Jan-08-24 08:30AM
Jan-06-24 11:02AM
Jan-02-24 07:19PM
Dec-20-23 01:50PM
Dec-19-23 11:41AM
Dec-15-23 02:30PM
Dec-12-23 12:46PM
08:00AM
Dec-10-23 05:00PM
Dec-05-23 10:32AM
Nov-30-23 11:31AM
Nov-16-23 12:17PM
Nov-13-23 09:50PM
Nov-12-23 08:18AM
Nov-09-23 10:01PM
Nov-02-23 09:00AM
Nov-01-23 12:32PM
Oct-31-23 09:52PM
12:14PM
09:36AM
09:30AM
08:43AM
08:15AM
07:09AM
(Associated Press Finance)
07:00AM
Oct-30-23 11:37AM
Oct-27-23 11:36AM
08:00AM
Oct-25-23 10:02AM
Oct-20-23 12:04PM
Oct-18-23 08:00AM
Oct-16-23 08:00AM
07:30AM
Oct-13-23 12:44PM
10:30AM
08:00AM
Oct-12-23 11:29AM
09:00AM
Oct-11-23 10:30AM
09:15AM
08:15AM
Oct-10-23 04:45PM
08:00AM
Sep-29-23 01:43PM
Sep-26-23 12:33PM
Sep-21-23 07:11PM
Sep-20-23 12:12PM
Sep-18-23 04:07PM
(Investor's Business Daily)
11:36AM
09:59AM
Aug-31-23 11:31AM
Aug-22-23 08:00AM
Aug-08-23 06:20AM
Aug-04-23 04:33PM
Aug-02-23 07:32PM
Aug-01-23 05:00PM
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Stein Steven H EVP & Chief Medical Officer Jan 03 '24 Sale 65.51 7,365 482,481 90,218 Jan 05 12:27 PM Iyengar Vijay K EVP, GMAPPS Jan 02 '24 Sale 65.00 657 42,705 43,412 Jan 04 01:05 PM Tray Thomas Principal Accounting Officer Dec 13 '23 Sale 62.37 1,067 66,549 23,436 Dec 14 02:11 PM Tray Thomas Principal Accounting Officer Dec 12 '23 Sale 57.36 210 12,046 24,503 Dec 14 02:11 PM SWAIN PAULA J EVP, Human Resources Sep 01 '23 Sale 65.13 8,449 550,283 77,530 Sep 06 04:00 PM Stein Steven H EVP & Chief Medical Officer Aug 01 '23 Sale 63.28 21,511 1,361,216 97,583 Aug 03 04:00 PM
Index RUT
P/E -
EPS (ttm) -19.94
Insider Own 18.78%
Shs Outstand 19.88M
Perf Week 4.61%
Market Cap 5.31B
Forward P/E -
EPS next Y -14.14
Insider Trans 12.22%
Shs Float 16.16M
Perf Month 5.04%
Income -373.63M
PEG -
EPS next Q -6.23
Inst Own 93.67%
Short Float 20.18%
Perf Quarter 12.79%
Sales 0.00M
P/S -
EPS this Y -16.32%
Inst Trans -1.70%
Short Ratio 5.80
Perf Half Y 76.29%
Book/sh 20.39
P/B 13.09
EPS next Y 39.20%
ROA -74.49%
Short Interest 3.26M
Perf Year 10.90%
Cash/sh 31.87
P/C 8.38
EPS next 5Y 0.00%
ROE -123.98%
52W Range 119.76 - 322.67
Perf YTD 15.41%
Dividend Est. -
P/FCF -
EPS past 5Y -55.24%
ROI -71.58%
52W High -17.24%
Beta -0.47
Dividend TTM -
Quick Ratio 5.38
Sales past 5Y 0.00%
Gross Margin -
52W Low 122.98%
ATR (14) 17.41
Dividend Ex-Date -
Current Ratio 5.38
EPS Y/Y TTM -15.71%
Oper. Margin 0.00%
RSI (14) 56.75
Volatility 5.06% 6.59%
Employees 376
Debt/Eq 0.29
Sales Y/Y TTM -
Profit Margin -
Recom 1.29
Target Price 394.54
Option/Short Yes / Yes
LT Debt/Eq 0.29
EPS Q/Q -13.93%
Payout -
Rel Volume 0.78
Prev Close 258.81
Sales Surprise -
EPS Surprise -8.42%
Sales Q/Q -
Earnings Feb 28 BMO
Avg Volume 562.63K
Price 267.04
SMA20 4.28%
SMA50 13.12%
SMA200 32.34%
Trades
Volume 441,051
Change 3.18%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-15-24 Upgrade
B. Riley Securities
Sell → Neutral
$155 → $270
Mar-06-24 Initiated
Citigroup
Buy
$382
Feb-26-24 Downgrade
B. Riley Securities
Neutral → Sell
$155
Dec-20-22 Reiterated
Oppenheimer
Outperform
$170 → $250
Dec-19-22 Upgrade
Raymond James
Underperform → Mkt Perform
Dec-19-22 Reiterated
Piper Sandler
Overweight
$203 → $280
Dec-19-22 Reiterated
H.C. Wainwright
Buy
$170 → $225
Jul-08-22 Downgrade
B. Riley Securities
Buy → Neutral
$131 → $75
Oct-07-21 Initiated
Jefferies
Buy
$151
Aug-06-21 Upgrade
BMO Capital Markets
Market Perform → Outperform
May-20-21 Resumed
Goldman
Buy
$195
Nov-24-20 Resumed
Evercore ISI
Outperform
$180
Nov-06-20 Reiterated
H.C. Wainwright
Buy
$165 → $184
Jul-31-20 Initiated
Piper Sandler
Overweight
$208
Jun-05-20 Initiated
BMO Capital Markets
Market Perform
$135
May-05-20 Initiated
Chardan Capital Markets
Buy
$205
Jan-30-20 Initiated
Canaccord Genuity
Buy
$198
Jan-09-20 Upgrade
UBS
Neutral → Buy
$125 → $127
Nov-07-19 Reiterated
H.C. Wainwright
Buy
$225 → $215
Jun-25-19 Initiated
Stifel
Hold
Show Previous Ratings
Today 04:43AM
Mar-26-24 09:53AM
Mar-22-24 06:15AM
Mar-19-24 05:50AM
Mar-18-24 11:58PM
08:01PM
Loading…
08:01PM
04:47PM
04:12PM
04:04PM
03:15PM
(Investor's Business Daily)
07:00AM
(The Wall Street Journal)
Mar-17-24 08:50AM
05:50AM
Mar-15-24 04:35PM
04:14PM
(Investor's Business Daily)
03:50PM
Loading…
03:50PM
02:34PM
(The Wall Street Journal)
01:45PM
12:56PM
12:09PM
10:17AM
10:01AM
09:30AM
07:45AM
(Investor's Business Daily)
05:35AM
Mar-14-24 04:25PM
(Investor's Business Daily) -10.77%
04:15PM
12:11PM
Mar-09-24 05:52AM
Mar-06-24 04:05PM
08:00AM
Loading…
Mar-05-24 08:00AM
06:03AM
Feb-28-24 07:01AM
07:00AM
06:45AM
(Associated Press Finance)
Feb-26-24 04:04PM
(Investor's Business Daily)
10:52AM
(Investor's Business Daily)
Feb-23-24 05:43AM
Feb-21-24 08:00AM
Feb-13-24 01:36PM
Feb-08-24 08:00AM
Feb-06-24 04:05PM
11:29AM
(The Wall Street Journal)
11:28AM
(Investor's Business Daily)
Jan-29-24 08:00AM
02:59AM
Jan-22-24 08:00AM
01:29AM
Jan-04-24 08:00AM
01:21AM
Jan-03-24 04:30PM
Dec-30-23 06:50AM
Dec-22-23 04:30PM
Dec-19-23 01:02PM
10:16AM
Dec-15-23 11:01PM
Dec-07-23 08:45AM
Nov-27-23 04:30PM
09:50AM
Nov-24-23 10:00AM
Nov-21-23 08:00AM
Nov-17-23 10:46AM
(Investor's Business Daily)
Nov-16-23 03:03PM
Nov-15-23 04:45PM
Nov-14-23 10:56AM
Nov-13-23 04:40PM
Nov-10-23 08:00AM
07:30AM
Nov-07-23 04:54AM
Nov-06-23 08:00AM
06:29AM
(Associated Press Finance)
Nov-04-23 12:16PM
Nov-02-23 04:05PM
Oct-27-23 10:01AM
Oct-17-23 09:53AM
Oct-12-23 04:05PM
07:49AM
Oct-02-23 11:51AM
Sep-29-23 12:41PM
Sep-28-23 10:30PM
04:01PM
Sep-27-23 09:53AM
Sep-25-23 08:08PM
Sep-21-23 09:25AM
09:25AM
01:00AM
Sep-20-23 07:00AM
Sep-14-23 04:30PM
Sep-13-23 04:10PM
(Investor's Business Daily) +7.67%
09:10AM
Sep-11-23 07:00AM
Sep-09-23 03:59PM
Sep-04-23 03:43PM
Aug-30-23 08:54AM
Aug-23-23 06:40AM
Aug-14-23 07:02PM
Aug-08-23 08:50AM
08:00AM
Jul-17-23 08:00AM
Jul-10-23 09:32AM
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 15 '23 Option Exercise 87.92 2,000 175,840 7,667 Dec 18 04:30 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 15 '23 Sale 238.50 2,000 477,000 5,667 Dec 18 04:30 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 14 '23 Option Exercise 87.92 2,000 175,840 7,667 Dec 18 04:30 PM BAKER BROS. ADVISORS LP Director Dec 14 '23 Buy 228.32 20,633 4,710,893 1,793,403 Dec 14 06:10 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 14 '23 Sale 232.50 2,000 465,000 5,667 Dec 18 04:30 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 13 '23 Option Exercise 87.92 2,500 219,800 8,167 Dec 14 04:30 PM BAKER BROS. ADVISORS LP Director Dec 13 '23 Buy 219.39 81,159 17,805,684 1,774,294 Dec 14 06:10 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 13 '23 Sale 225.40 2,500 563,500 5,667 Dec 14 04:30 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 12 '23 Option Exercise 87.92 1,300 114,296 6,967 Dec 14 04:30 PM BAKER BROS. ADVISORS LP Director Dec 12 '23 Buy 218.31 34,578 7,548,616 1,699,129 Dec 14 06:09 PM Waltermire Robert E. Senior VP, Chief Pharma Dev. Dec 12 '23 Sale 217.85 1,300 283,200 5,667 Dec 14 04:30 PM Lynch Brian Joseph SVP and General Counsel Dec 05 '23 Option Exercise 87.09 1,000 87,090 16,001 Dec 06 04:30 PM Lynch Brian Joseph SVP and General Counsel Dec 05 '23 Sale 227.33 1,000 227,330 15,001 Dec 06 04:30 PM Lynch Brian Joseph SVP and General Counsel Dec 04 '23 Option Exercise 81.16 1,800 146,090 16,801 Dec 06 04:30 PM Lynch Brian Joseph SVP and General Counsel Dec 04 '23 Sale 218.87 1,800 393,964 15,001 Dec 06 04:30 PM Lynch Brian Joseph SVP and General Counsel Nov 30 '23 Option Exercise 73.75 3,000 221,250 18,001 Dec 01 04:30 PM Lynch Brian Joseph SVP and General Counsel Nov 30 '23 Sale 204.58 3,000 613,730 15,001 Dec 01 04:30 PM Lynch Brian Joseph SVP and General Counsel Nov 29 '23 Option Exercise 73.75 4,000 295,000 19,001 Dec 01 04:30 PM Lynch Brian Joseph SVP and General Counsel Nov 29 '23 Sale 199.19 4,000 796,750 15,001 Dec 01 04:30 PM BAKER BROS. ADVISORS LP Director Nov 21 '23 Buy 188.47 64,350 12,128,340 1,667,104 Nov 21 06:15 PM BAKER BROS. ADVISORS LP Director Nov 20 '23 Buy 185.74 20,709 3,846,575 1,607,668 Nov 21 06:14 PM BAKER BROS. ADVISORS LP Director Nov 17 '23 Buy 174.70 46,370 8,100,704 1,588,541 Nov 21 06:14 PM BAKER BROS. ADVISORS LP Director Nov 15 '23 Buy 161.97 15,199 2,461,721 1,545,775 Nov 15 05:13 PM BAKER BROS. ADVISORS LP Director Nov 14 '23 Buy 154.00 37,660 5,799,653 1,500,227 Nov 15 05:12 PM BAKER BROS. ADVISORS LP Director Nov 14 '23 Buy 156.42 34,188 5,347,837 1,531,757 Nov 15 05:13 PM BAKER BROS. ADVISORS LP Director Nov 13 '23 Buy 143.21 69,839 10,001,368 1,465,494 Nov 15 05:12 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite